应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
PFE 辉瑞
盘后交易 02-24 16:09:20 EST
27.14
+0.08
+0.30%
盘后
27.10
-0.04
-0.15%
16:09 EST
最高
27.42
最低
27.08
成交量
3,455万
今开
27.14
昨收
27.06
日振幅
1.26%
总市值
1,543亿
流通市值
1,540亿
总股本
56.86亿
成交额
9.40亿
换手率
0.61%
流通股本
56.76亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
美国FDA全面批准辉瑞Braftovi联合疗法用于一线治疗转移性结直肠癌
美股速递 · 03:30
美国FDA全面批准辉瑞Braftovi联合疗法用于一线治疗转移性结直肠癌
FDA正式批准Encorafenib用于治疗BRAF V600E突变型转移性结直肠癌
美股速递 · 01:57
FDA正式批准Encorafenib用于治疗BRAF V600E突变型转移性结直肠癌
豪掷近5亿美元辉瑞(PFE.US)牵手中国biotech，加码在华减肥药市场
智通财经 · 02-24 14:56
豪掷近5亿美元辉瑞(PFE.US)牵手中国biotech，加码在华减肥药市场
先为达生物携手辉瑞中国，达成埃诺格鲁肽商业化战略合作协议
市场资讯 · 02-24 10:23
先为达生物携手辉瑞中国，达成埃诺格鲁肽商业化战略合作协议
杭州Sciwind生物与辉瑞中国就新一代Ecnoglutide注射剂商业化达成战略合作协议
美股速递 · 02-24 09:30
杭州Sciwind生物与辉瑞中国就新一代Ecnoglutide注射剂商业化达成战略合作协议
辉瑞第四财季净利润达14.2亿卢比
投资观察 · 02-09
辉瑞第四财季净利润达14.2亿卢比
辉瑞抗感染创新药获批儿科适应证
格隆汇 · 02-06
辉瑞抗感染创新药获批儿科适应证
FDA授予Hympavzi®（Marstacimab）优先审评资格，用于治疗存在重大医疗需求的两类血友病A或B患者群体
美股速递 · 02-06
FDA授予Hympavzi®（Marstacimab）优先审评资格，用于治疗存在重大医疗需求的两类血友病A或B患者群体
辉瑞推出优惠计划：覆盖女性健康、偏头痛、关节炎及罕见病等30多个品牌
美股速递 · 02-06
辉瑞推出优惠计划：覆盖女性健康、偏头痛、关节炎及罕见病等30多个品牌
辉瑞(PFE.US)超长效减重疗法取得积极顶线结果 将启动3期试验
智通财经 · 02-04
辉瑞(PFE.US)超长效减重疗法取得积极顶线结果 将启动3期试验
超1/3大额并购配置CVR，对赌因何活跃？
研发客 · 02-04
超1/3大额并购配置CVR，对赌因何活跃？
辉瑞CEO表示，公司计划在2026年开展约20项与减肥药相关的临床试验。
格隆汇 · 02-03
辉瑞CEO表示，公司计划在2026年开展约20项与减肥药相关的临床试验。
药品需求旺盛，辉瑞四季度利润超市场预期
环球市场播报 · 02-03
药品需求旺盛，辉瑞四季度利润超市场预期
辉瑞(PFE.US)Q4业绩超预期 但投资者更关注减肥药能否扛起增长大旗
智通财经 · 02-03
辉瑞(PFE.US)Q4业绩超预期 但投资者更关注减肥药能否扛起增长大旗
周二值得关注的股票：PayPal、百事可乐、美国超微公司——华尔街日报
投资观察 · 02-03
周二值得关注的股票：PayPal、百事可乐、美国超微公司——华尔街日报
辉瑞公布GLP-1新药数据：可实现稳定减重
南方财经网 · 02-03
辉瑞公布GLP-1新药数据：可实现稳定减重
辉瑞预计制造优化计划将在2026年和2027年分别额外节省7亿美元和2亿美元
美股速递 · 02-03
辉瑞预计制造优化计划将在2026年和2027年分别额外节省7亿美元和2亿美元
辉瑞预期制造优化计划首阶段将在2026年额外节省7亿美元、2027年再省2亿美元
美股速递 · 02-03
辉瑞预期制造优化计划首阶段将在2026年额外节省7亿美元、2027年再省2亿美元
辉瑞股价盘前下跌2.1%
每日经济新闻 · 02-03
辉瑞股价盘前下跌2.1%
辉瑞高管称肥胖研究数据提示更高剂量或可提升疗效
美股速递 · 02-03
辉瑞高管称肥胖研究数据提示更高剂量或可提升疗效
公司概况
公司名称：
辉瑞
所属市场：
NYSE
上市日期：
--
主营业务：
辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。
发行价格：
--
{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":27.14,"timestamp":1771966800000,"preClose":27.06,"halted":0,"volume":34547642,"hourTrading":{"tag":"盘后","latestPrice":27.1,"preClose":27.14,"latestTime":"16:09 EST","volume":5704451,"amount":154818435.055136,"timestamp":1771967355619,"change":-0.04,"changeRate":-0.001474,"amplitude":0.004053},"delay":0,"changeRate":0.002956393200295708,"floatShares":5675908374,"shares":5685707552,"eps":1.36,"marketStatus":"盘后交易","change":0.08,"latestTime":"02-24 16:09:20 EST","open":27.14,"high":27.42,"low":27.08,"amount":940324836.770252,"amplitude":0.012565,"askPrice":27.15,"askSize":2700,"bidPrice":27.05,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":1.36,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1771981200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":-819144000000,"exchange":"NYSE","adjPreClose":27.06,"dividendRate":0.063412,"preHourTrading":{"tag":"盘前","latestPrice":27.16,"preClose":27.06,"latestTime":"09:29 EST","volume":56933,"amount":1542714.810459,"timestamp":1771943385523,"change":0.1,"changeRate":0.003695,"amplitude":0.006652},"postHourTrading":{"tag":"盘后","latestPrice":27.1,"preClose":27.14,"latestTime":"16:09 EST","volume":5704451,"amount":154818435.055136,"timestamp":1771967355619,"change":-0.04,"changeRate":-0.001474,"amplitude":0.004053},"volumeRatio":0.980523,"optionData":{"bulkOrders":[{"symbol":"PFE","call":false,"expireDate":1789704000000,"strike":"24.0","timestamp":1771952574027,"price":0.83,"volume":7582,"amount":629306,"type":"+"},{"symbol":"PFE","call":false,"expireDate":1773979200000,"strike":"25.0","timestamp":1771949738909,"price":0.09,"volume":4500,"amount":40500,"type":"-"}]},"impliedVol":0.266,"impliedVolPercentile":0.3267},"requestUrl":"/m/hq/s/PFE/wiki","defaultTab":"wiki","newsList":[{"id":"1149231277","title":"美国FDA全面批准辉瑞Braftovi联合疗法用于一线治疗转移性结直肠癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1149231277","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149231277?lang=zh_cn&edition=full","pubTime":"2026-02-25 03:30","pubTimestamp":1771961452,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式授予辉瑞公司Braftovi联合疗法完全批准，该疗法将作为转移性结直肠癌的一线治疗方案。此次全面批准标志着该组合疗法在临床应用中迈出关键一步，为患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","SG9999001176.SGD","BK4588","SG9999002232.USD","IE00B19Z3581.USD","LU0234572021.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0868494617.USD","LU1894683264.USD","BK4533","LU0306807586.USD","SG9999013999.USD","BK4568","SG9999003800.SGD","LU0058720904.USD","LU0456855351.SGD","SG9999001176.USD","LU1883839398.USD","PFE","LU0306806265.USD","BK4585","LU1894683348.USD","SG9999002224.SGD","LU0321505439.SGD","BK4534","BK4599","SG9999011175.SGD","IE000M9KFDE8.USD","LU0321505868.SGD","LU0122379950.USD","IE00BLSP4452.SGD","BK4550","LU1057294990.SGD","LU0225284248.USD","LU0985481810.HKD","LU1066053197.SGD","BK4007","IE00BBT3K403.USD","BK4592","LU0170899867.USD","IE00BLSP4239.USD","SGXZ57979304.SGD","BK4581","LU0225771236.USD","LU1066051498.USD"],"gpt_icon":0},{"id":"1195345777","title":"FDA正式批准Encorafenib用于治疗BRAF V600E突变型转移性结直肠癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1195345777","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195345777?lang=zh_cn&edition=full","pubTime":"2026-02-25 01:57","pubTimestamp":1771955860,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式授予Encorafenib传统批准，用于治疗携带BRAF V600E突变的转移性结直肠癌患者。这一决定为特定基因突变类型的晚期结直肠癌患者提供了新的靶向治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU0306807586.USD","IE0002270589.USD","IE000M9KFDE8.USD","LU0225284248.USD","LU0234572021.USD","BK4599","LU1883839398.USD","BK4007","BK4588","BK4585","IE00B19Z3B42.SGD","SG9999001176.USD","LU1023059063.AUD","LU0289739699.SGD","IE00BLSP4239.USD","LU1894683264.USD","LU0058720904.USD","LU1057294990.SGD","SG9999002224.SGD","SG9999011175.SGD","BK4592","SG9999013999.USD","LU0306806265.USD","LU0456855351.SGD","BK4533","LU1894683348.USD","LU0985481810.HKD","LU0170899867.USD","LU0225771236.USD","PFE","BK4550","SG9999003800.SGD","IE00B19Z3581.USD","SG9999001176.SGD","IE00BBT3K403.USD","LU0122379950.USD","LU0321505439.SGD","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4568","LU1066053197.SGD","LU0868494617.USD","SG9999002232.USD","BK4581","LU1066051498.USD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2613110762","title":"豪掷近5亿美元辉瑞(PFE.US)牵手中国biotech，加码在华减肥药市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2613110762","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613110762?lang=zh_cn&edition=full","pubTime":"2026-02-24 14:56","pubTimestamp":1771916204,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国制药巨头辉瑞公司与本土初创企业杭州先为达生物科技股份有限公司达成协议，以获得后者一款减肥疗法在中国的独家商业化权益，此举旨在强化其在高增长减肥市场的布局。该药近期在中国获批用于治疗糖尿病，目前其用于减肥的适应症正处于监管审查阶段。辉瑞一直大力追赶在减肥药领域的领先者。辉瑞正寻求在后疫情时代进行业务重建。在中国减肥药市场，辉瑞将直面全球制药巨头及信达生物等本土竞争对手的挑战。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"豪掷近5亿美元辉瑞(PFE.US)牵手中国biotech，加码在华减肥药市场","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","IE00B19Z3581.USD","LU0321505439.SGD","LU0289739699.SGD","SGXZ57979304.SGD","BK4599","SG9999011175.SGD","BK4534","LU0234572021.USD","LU1057294990.SGD","LU0306807586.USD","SG9999003800.SGD","SG9999001176.USD","BK4568","PFE","IE00B19Z3B42.SGD","LU1894683264.USD","SG9999001176.SGD","LU0985481810.HKD","SG9999013999.USD","BK4550","IE0002270589.USD","BK4007","LU1066053197.SGD","LU1066051498.USD","LU0456855351.SGD","SG9999002224.SGD","IE000M9KFDE8.USD","LU0868494617.USD","IE00BBT3K403.USD","BK4592","LU1883839398.USD","LU0321505868.SGD","LU1894683348.USD","LU1023059063.AUD","LU0170899867.USD","LU0122379950.USD","BK4533","BK4585","LU0058720904.USD","IE00BLSP4452.SGD","LU0225771236.USD","LU0306806265.USD","SG9999002232.USD","IE00BLSP4239.USD","BK4588","LU0225284248.USD"],"gpt_icon":1},{"id":"2613897750","title":"先为达生物携手辉瑞中国，达成埃诺格鲁肽商业化战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2613897750","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613897750?lang=zh_cn&edition=full","pubTime":"2026-02-24 10:23","pubTimestamp":1771899780,"startTime":"0","endTime":"0","summary":"2月24日消息，杭州先为达生物科技股份有限公司与辉瑞中国今日宣布，双方就新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液 达成商业化战略合作协议。先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付款、注册及销售里程碑付款。 埃诺格鲁肽是由先为达生物自主研发的新一代cAMP偏向型GLP-1受体激动剂，将为2型糖尿病及长期体重管理相关患者提供更为精准的治疗方案。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-24/doc-inhnwrqu6119933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1894683348.USD","LU0058720904.USD","LU0321505439.SGD","BK4585","LU0170899867.USD","BK4581","LU1023059063.AUD","LU0306806265.USD","BK4007","IE00BLSP4239.USD","SG9999001176.USD","PFE","LU0985481810.HKD","BK4599","LU1066053197.SGD","LU0456855351.SGD","IE00B19Z3B42.SGD","LU0321505868.SGD","SG9999011175.SGD","SGXZ57979304.SGD","91078","IE00BBT3K403.USD","IE00BLSP4452.SGD","SG9999001176.SGD","LU0234572021.USD","BK4533","IE000M9KFDE8.USD","LU1066051498.USD","SG9999003800.SGD","SG9999013999.USD","LU0225284248.USD","BK4568","BK4534","BK4588","LU0306807586.USD","LU1883839398.USD","SG9999002232.USD","BK4550","SG9999002224.SGD","LU0122379950.USD","LU0289739699.SGD","LU1057294990.SGD","LU0225771236.USD","IE00B19Z3581.USD","LU1894683264.USD","IE0002270589.USD","LU0868494617.USD","BK4592"],"gpt_icon":1},{"id":"1110833815","title":"杭州Sciwind生物与辉瑞中国就新一代Ecnoglutide注射剂商业化达成战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1110833815","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110833815?lang=zh_cn&edition=full","pubTime":"2026-02-24 09:30","pubTimestamp":1771896617,"startTime":"0","endTime":"0","summary":"杭州Sciwind生物科技公司与辉瑞中国已正式签署战略合作协议，共同推进新一代Ecnoglutide注射剂的商业化进程。此次合作旨在整合双方在研发与市场渠道方面的优势，加速该创新药物在中国市场的应用与推广。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002224.SGD","LU1066051498.USD","02252","IE00BLSP4239.USD","SG9999002232.USD","SGXZ57979304.SGD","LU0321505439.SGD","LU1883839398.USD","SG9999001176.SGD","BK4585","BK4581","LU0985481810.HKD","LU1894683348.USD","IE00BBT3K403.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU0170899867.USD","LU0225284248.USD","IE00B19Z3581.USD","BK4599","LU1894683264.USD","BK4592","SG9999011175.SGD","LU0058720904.USD","LU1066053197.SGD","LU0456855351.SGD","BK4007","BK4534","LU0225771236.USD","LU1023059063.AUD","PFE","LU1057294990.SGD","LU0306806265.USD","LU0289739699.SGD","LU0306807586.USD","BK4533","BK4588","BK4550","IE000M9KFDE8.USD","LU0234572021.USD","BK4568","LU0868494617.USD","SG9999003800.SGD","SG9999013999.USD","LU0321505868.SGD","IE00BLSP4452.SGD","SG9999001176.USD","LU0122379950.USD"],"gpt_icon":0},{"id":"1182484790","title":"辉瑞第四财季净利润达14.2亿卢比","url":"https://stock-news.laohu8.com/highlight/detail?id=1182484790","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182484790?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:49","pubTimestamp":1770648556,"startTime":"0","endTime":"0","summary":"辉瑞有限公司最新财报显示，公司在第四财季实现净利润14.2亿卢比。同期，公司营业收入为64.5亿卢比。财报数据反映出企业当季的盈利能力和运营表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4239.USD","BK4007","LU0225284248.USD","PFE","SG9999003800.SGD","IE00BLSP4452.SGD","IE00B19Z3B42.SGD","BK4599","LU1894683264.USD","LU0985481810.HKD","LU0868494617.USD","SG9999002232.USD","BK4534","LU0321505439.SGD","SG9999001176.SGD","BK4585","IE00BBT3K403.USD","LU0289739699.SGD","BK4581","LU1894683348.USD","SG9999002224.SGD","IE000M9KFDE8.USD","LU0170899867.USD","LU1057294990.SGD","IE00B19Z3581.USD","LU0306807586.USD","LU1066051498.USD","BK4550","SG9999011175.SGD","LU1023059063.AUD","BK4568","LU1066053197.SGD","LU0321505868.SGD","BK4533","LU0306806265.USD","LU0058720904.USD","BK4592","LU0225771236.USD","LU0122379950.USD","SG9999013999.USD","SG9999001176.USD","LU0456855351.SGD","BK4588","IE0002270589.USD","LU0234572021.USD","LU1883839398.USD","SGXZ57979304.SGD"],"gpt_icon":0},{"id":"2609591202","title":"辉瑞抗感染创新药获批儿科适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2609591202","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609591202?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:20","pubTimestamp":1770387607,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4568","LU0985481810.HKD","SG9999002224.SGD","IE0002270589.USD","BK1574","BK4592","IE00B19Z3B42.SGD","LU1066051498.USD","PFE","SG9999002232.USD","BK4585","LU1066053197.SGD","SG9999013999.USD","LU0306807586.USD","LU0225771236.USD","BK4588","SG9999003800.SGD","BK4007","LU0225284248.USD","LU1894683348.USD","LU0321505439.SGD","LU1023059063.AUD","BK4550","LU0058720904.USD","LU0456855351.SGD","LU0122379950.USD","LU1894683264.USD","LU0170899867.USD","LU1057294990.SGD","IE00BLSP4452.SGD","SGXZ57979304.SGD","IE00BLSP4239.USD","BK4533","BK4581","SG9999001176.USD","IE00B19Z3581.USD","BK4534","SG9999011175.SGD","BK1161","LU0289739699.SGD","LU0868494617.USD","LU0306806265.USD","BK4599","IE000M9KFDE8.USD","LU0234572021.USD","LU0321505868.SGD","IE00BBT3K403.USD","LU1883839398.USD","SG9999001176.SGD"],"gpt_icon":0},{"id":"1119071271","title":"FDA授予Hympavzi®（Marstacimab）优先审评资格，用于治疗存在重大医疗需求的两类血友病A或B患者群体","url":"https://stock-news.laohu8.com/highlight/detail?id=1119071271","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119071271?lang=zh_cn&edition=full","pubTime":"2026-02-06 19:45","pubTimestamp":1770378357,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已授予Hympavzi®（Marstacimab）补充生物制剂许可申请（sBLA）优先审评资格。该药物旨在治疗存在重大医疗需求的两类血友病A或B患者群体。\n优先审评资格的授予，意味着FDA认为该疗法有潜力在安全性或有效性方面为患者提供显著改善。此举有望加速Hympavzi®的审批进程，为亟需新治疗选择的血友病患者带来希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","BK4592","IE00B19Z3581.USD","LU0985481810.HKD","IE00BLSP4452.SGD","LU1066053197.SGD","LU0170899867.USD","LU0289739699.SGD","LU0456855351.SGD","BK4534","SG9999011175.SGD","IE0002270589.USD","IE000M9KFDE8.USD","SG9999002224.SGD","LU1894683264.USD","BK4007","LU0306806265.USD","SG9999013999.USD","LU1894683348.USD","IE00B19Z3B42.SGD","LU0122379950.USD","BK4585","SG9999001176.SGD","SG9999002232.USD","BK4588","PFE","LU0225284248.USD","BK4550","LU0058720904.USD","IE00BLSP4239.USD","LU1883839398.USD","SG9999003800.SGD","LU0321505439.SGD","IE00BBT3K403.USD","LU1066051498.USD","LU0868494617.USD","SG9999001176.USD","LU1023059063.AUD","LU1057294990.SGD","BK4533","LU0306807586.USD","LU0321505868.SGD","BK4568","SGXZ57979304.SGD","LU0225771236.USD","BK4599","BK4581"],"gpt_icon":0},{"id":"1191151847","title":"辉瑞推出优惠计划：覆盖女性健康、偏头痛、关节炎及罕见病等30多个品牌","url":"https://stock-news.laohu8.com/highlight/detail?id=1191151847","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191151847?lang=zh_cn&edition=full","pubTime":"2026-02-06 08:14","pubTimestamp":1770336852,"startTime":"0","endTime":"0","summary":"辉瑞公司近日宣布推出一项新的优惠计划，该计划涵盖超过30个品牌，涉及女性健康、偏头痛、关节炎、罕见疾病等多个治疗领域。通过这一计划，患者有望在购买相关药物时获得费用节省。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BK4592","LU0306806265.USD","LU0306807586.USD","SG9999003800.SGD","BK4568","BK4581","LU0868494617.USD","SG9999001176.USD","IE0002270589.USD","SG9999002224.SGD","LU0122379950.USD","BK4007","SG9999002232.USD","IE00BBT3K403.USD","BK4588","LU0225771236.USD","LU0170899867.USD","LU1057294990.SGD","BK4599","LU1894683348.USD","SGXZ57979304.SGD","PFE","BK4534","IE00B19Z3B42.SGD","LU0234572021.USD","LU0289739699.SGD","BK4585","LU0321505868.SGD","LU0225284248.USD","LU0321505439.SGD","SG9999013999.USD","LU0985481810.HKD","LU1023059063.AUD","IE000M9KFDE8.USD","LU0058720904.USD","IE00BLSP4239.USD","LU1066053197.SGD","SG9999001176.SGD","BK4550","LU1066051498.USD","LU1894683264.USD","LU0456855351.SGD","LU1883839398.USD","BK4533","SG9999011175.SGD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2608952381","title":"辉瑞(PFE.US)超长效减重疗法取得积极顶线结果 将启动3期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2608952381","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608952381?lang=zh_cn&edition=full","pubTime":"2026-02-04 07:53","pubTimestamp":1770162821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月3日，辉瑞宣布，其超长效注射用GLP-1受体激动剂PF'3944在2b期VESPER-3研究中取得积极顶线结果。该研究针对肥胖或超重、不合并2型糖尿病的成人患者，评估每月一次维持给药方案。结果显示，治疗第28周，第1组和第3组患者的体重分别较安慰剂组降低了10%和12.3%。安慰剂组中没有因AEs而中止治疗的情况。辉瑞计划推进大规模肥胖开发项目，预计在2026年启动20项以上临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"辉瑞(PFE.US)超长效减重疗法取得积极顶线结果 将启动3期试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0225284248.USD","LU0170899867.USD","BK4533","BK4585","SG9999001176.USD","BK4534","LU0321505439.SGD","BK4007","SG9999003800.SGD","LU0306807586.USD","LU1057294990.SGD","LU1066051498.USD","LU0985481810.HKD","IE00BBT3K403.USD","BK4568","BK4550","LU1894683264.USD","SG9999002224.SGD","SG9999002232.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0868494617.USD","SG9999001176.SGD","LU0122379950.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","SGXZ57979304.SGD","BK4581","LU0321505868.SGD","LU0234572021.USD","IE000M9KFDE8.USD","LU0306806265.USD","LU0058720904.USD","BK4588","LU0225771236.USD","IE0002270589.USD","LU1066053197.SGD","LU1883839398.USD","LU1894683348.USD","SG9999013999.USD","PFE","LU0456855351.SGD","SG9999011175.SGD","BK4599","LU1023059063.AUD","BK4592"],"gpt_icon":1},{"id":"2608114387","title":"超1/3大额并购配置CVR，对赌因何活跃？","url":"https://stock-news.laohu8.com/highlight/detail?id=2608114387","media":"研发客","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608114387?lang=zh_cn&edition=full","pubTime":"2026-02-04 05:00","pubTimestamp":1770152451,"startTime":"0","endTime":"0","summary":"改变打法据BioPharma Dive统计，2025年下半年，约有三分之一的大额并购交易采用了CVR模式。交易条款包括每股65.60美元的固定现金对价，以及最高每股20.65美元的CVR款项。CVR 与未来里程碑达成情况挂钩，仅当相关目标按期实现时，收购方才需支付该笔额外款项。Genmab在竞购的过程中更是明确表示对CVR不感兴趣，希望以一次性付款的方式完成交易。此外，德勤的调查发现，45%的生物制药领导者将并购列为近期的首要战略重点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204050313a478cb18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204050313a478cb18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4161","LU0154236417.USD","BK4007","IE00BZ1G4Q59.USD","JNJ","IE00BKVL7J92.USD","NVO","PFE","BK4599","BK4532","BK4588","LU1093756168.USD","BK4585","LU1093756325.SGD","RHHBY"],"gpt_icon":1},{"id":"2608808896","title":"辉瑞CEO表示，公司计划在2026年开展约20项与减肥药相关的临床试验。","url":"https://stock-news.laohu8.com/highlight/detail?id=2608808896","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608808896?lang=zh_cn&edition=full","pubTime":"2026-02-03 23:14","pubTimestamp":1770131691,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BLSP4452.SGD","LU0868494617.USD","IE0002270589.USD","BK4550","IE00B19Z3581.USD","SG9999011175.SGD","BK4581","BK4585","SG9999002232.USD","LU0170899867.USD","BK4533","LU1883839398.USD","BK4568","BK4599","LU1057294990.SGD","PFE","LU1066053197.SGD","LU0321505439.SGD","SGXZ57979304.SGD","LU0321505868.SGD","SG9999001176.SGD","LU0985481810.HKD","LU1023059063.AUD","LU1894683264.USD","LU0225284248.USD","SG9999001176.USD","IE00BBT3K403.USD","BK4534","LU0122379950.USD","LU0456855351.SGD","SG9999013999.USD","SG9999002224.SGD","BK4592","LU0225771236.USD","LU0058720904.USD","BK4588","LU0306806265.USD","BK4007","LU0234572021.USD","IE00B19Z3B42.SGD","LU1066051498.USD","IE00BLSP4239.USD","SG9999003800.SGD","LU0306807586.USD","IE000M9KFDE8.USD","LU1894683348.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2608587944","title":"药品需求旺盛，辉瑞四季度利润超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2608587944","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608587944?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:08","pubTimestamp":1770124080,"startTime":"0","endTime":"0","summary":"专题：聚焦美股2025年第四季度财报\n 辉瑞于周二公布四季度业绩，公司利润超华尔街预期，业绩增长得益于阿哌沙班、维达全这类经典药物的需求持续走高。\n 据伦敦证券交易所集团汇总的数据，经调整后，辉瑞四季度每股收益为 66 美分，高于分析师此前 57 美分的预期。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4466d9e38820302c3ea1a8f2a1598904","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-03/doc-inhkpzpa3613400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1894683264.USD","LU0122379950.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU0868494617.USD","BK4585","BK4568","LU0456855351.SGD","BK4550","IE00BLSP4239.USD","SG9999002224.SGD","BK4592","LU1883839398.USD","LU1023059063.AUD","LU1066051498.USD","LU1894683348.USD","BK4534","LU0321505439.SGD","IE00BLSP4452.SGD","LU0985481810.HKD","LU0289739699.SGD","BK4533","LU0321505868.SGD","LU0234572021.USD","SG9999001176.USD","SG9999001176.SGD","LU0058720904.USD","BK4007","BK4581","LU0170899867.USD","LU1057294990.SGD","SG9999002232.USD","LU0306806265.USD","IE0002270589.USD","PFE","BK4599","SG9999013999.USD","BK4588","IE00BBT3K403.USD","LU1066053197.SGD","LU0225771236.USD","SG9999011175.SGD","LU0306807586.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","SG9999003800.SGD","LU0225284248.USD"],"gpt_icon":0},{"id":"2608787921","title":"辉瑞(PFE.US)Q4业绩超预期 但投资者更关注减肥药能否扛起增长大旗","url":"https://stock-news.laohu8.com/highlight/detail?id=2608787921","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608787921?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:06","pubTimestamp":1770123978,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，辉瑞公布了第四季度财报，尽管新冠相关产品需求持续萎缩，但公司营收与利润仍双双超出市场预期，同时公司重申了2026年的温和指引——该指引在去年12月公布时曾引发投资者担忧。另外，辉瑞还公布了其新型减肥疗法的初步数据，但披露信息有限。作为交换，辉瑞将获得为期三年的关税豁免。不过，在财报公布后，辉瑞股价盘前仍跌逾5%。他认为，辉瑞需要凭借在疗效或安全性上显著更优的产品，才能在该领域立足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4466d9e38820302c3ea1a8f2a1598904","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE000M9KFDE8.USD","SG9999001176.SGD","BK4599","BK4581","LU0868494617.USD","BK4533","BK4007","IE00BLSP4239.USD","LU0225771236.USD","SG9999001176.USD","PFE","LU0306807586.USD","LU0985481810.HKD","IE0002270589.USD","LU1066053197.SGD","BK4585","BK4534","LU1894683264.USD","LU0456855351.SGD","BK4568","LU0225284248.USD","SG9999002232.USD","IE00BLSP4452.SGD","IE00BBT3K403.USD","LU0321505868.SGD","LU1057294990.SGD","SG9999002224.SGD","SG9999003800.SGD","LU0289739699.SGD","LU0122379950.USD","SG9999013999.USD","IE00B19Z3581.USD","LU1883839398.USD","LU1894683348.USD","SG9999011175.SGD","BK4592","LU0306806265.USD","BK4588","LU0321505439.SGD","LU1066051498.USD","BK4550","SGXZ57979304.SGD","IE00B19Z3B42.SGD","LU0170899867.USD","LU1023059063.AUD","LU0234572021.USD","LU0058720904.USD"],"gpt_icon":1},{"id":"1182267894","title":"周二值得关注的股票：PayPal、百事可乐、美国超微公司——华尔街日报","url":"https://stock-news.laohu8.com/highlight/detail?id=1182267894","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182267894?lang=zh_cn&edition=full","pubTime":"2026-02-03 20:37","pubTimestamp":1770122252,"startTime":"0","endTime":"0","summary":"辉瑞最新财报显示，这家制药巨头季度销售额出现下滑，并意外录得亏损，主要因其新冠疫苗和抗病毒药物的市场需求持续萎缩。盘前交易中，该公司股价下跌约1%。PayPal预警称，由于核心品牌结算业务增长乏力，今年盈利可能面临下滑。该公司同时宣布，惠普首席执行官恩里克·洛雷斯将于三月接任PayPal CEO一职。消息公布后，其股价在盘前暴跌15%。美国超微公司与亿滋等企业将于美股收盘后公布业绩。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1116320737.USD","MRK","LU2360107325.USD","IE00B2B36J28.USD","LU1430594728.SGD","LU0661504455.SGD","LU1023059063.AUD","LU2355687059.USD","BK4581","LU1035773651.USD","LU1861214812.USD","LU0162691827.USD","LU0234572021.USD","IE00B4R5TH58.HKD","LU1989764664.SGD","PYPY","LU0985320562.USD","LU1989771016.USD","LU0553294199.USD","BK4554","BK4504","BK4566","LU1992135399.USD","IE00BBT3K403.USD","LU1037948897.HKD","LU1244550577.SGD","LU1929549753.HKD","LU0648001328.SGD","LU2272731782.SGD","IE00BQXX3D17.EUR","LU1934455863.HKD","IE00B1BXHZ80.USD","AMUU","LU0719512351.SGD","LU1003077747.HKD","LU1585245621.USD","IE0009356076.USD","LU0320765489.SGD","LU0211331839.USD","LU0266013472.USD","LU2089283258.USD","IE00BQXX3C00.GBP","LU0208291251.USD","LU0321505439.SGD","BK4575","PYPG","LU0306806265.USD","LU0949170772.SGD","LU2360106780.USD","LU0545039389.USD","IE00BFTCPJ56.SGD","LU1046421795.USD","LU0122379950.USD","LU1989772923.USD","SGXZ57979304.SGD","BK4170","SG9999001176.USD","IE0002270589.USD","SG9999001176.SGD","IE00BJJMRZ35.SGD","LU0456855351.SGD","LU1823568750.SGD","BK4568","DAMD","BK4212","LU0158827948.USD","LU1093756325.SGD","LU0306807586.USD","AMDU","BK4543","LU1069347547.HKD","LU2054465674.USD","LU1923623000.USD","LU0980610538.SGD","LU1883839398.USD","LU1244550494.USD","LU0082616367.USD","LU0274383776.USD","LU2125154778.USD","LU2458330243.SGD","BK4605","IE00B19Z3B42.SGD","LU0098860793.USD","LU1861220207.SGD","AMDY","LU1280957306.USD","LU1861559042.SGD","AMYY","LU1934455194.USD","LU2361044949.HKD","IE00B5949003.HKD","IE00BLSP4452.SGD","LU1057294990.SGD","BK4177","LU0203345920.USD","BK4524","LU1291159041.SGD","LU2250418816.HKD","IE00BSNM7G36.USD","LU1880398471.USD","LU1992135472.HKD","MDLZ","LU2360032135.SGD","LU1974910355.USD","LU0238689110.USD","LU1201861249.SGD","LU2361045086.USD","LU2023251221.USD","LU1242518857.USD","LU0965509283.SGD","LU1668664300.SGD","LU1803068979.SGD","LU2361044865.SGD","LU0058720904.USD","LU1894683264.USD","LU0072461881.USD","LU0265550946.USD","LU0348723411.USD","LU1934455277.USD","LU2931357623.SGD","LU1791807156.HKD","LU2098885051.SGD","AMDW","BK4512","LU0203347892.USD","LU2360107671.USD","SG9999015358.SGD","LU0127658192.USD","BK4529","BK4533","LU0823421416.USD","LU0642271901.SGD","LU0868494617.USD","SG9999015341.SGD","AMDL","SG9999002224.SGD","BK4535","LU1571399168.USD","LU2023250504.SGD","LU1066051811.HKD","LU0985481810.HKD","LU0006061336.USD","LU1861558580.USD","LU1162221912.USD","LU1316542783.SGD","LU1951200564.SGD","LU0477156953.USD","LU2458330169.SGD","SG9999013999.USD","SG9999014542.SGD","LU1699723380.USD","BK4559","LU0006306889.USD","LU0979878070.USD","LU0130102774.USD","LU0130517989.USD","LU1989772840.SGD","LU2468319806.SGD","LU1066051225.USD","BK4527","AMDG","LU0289960550.SGD","IE00BLSP4239.USD","SG9999014559.SGD","LU1066051498.USD","LU2089984988.USD","BK4585","LU0889565833.HKD","LU0225284248.USD","LU1244550221.USD","LU0823434740.USD","LU0320765646.SGD","LU2324357040.USD","BK4588","BK4007","LU2461242641.AUD","LU2125154935.USD","BK4598","LU1093756168.USD","LU1861217088.USD","LU2272731600.USD","LU2089985449.USD","LU1941712348.USD","IE00BZ199S13.USD","LU1880398554.USD","IE0009355771.USD","LU0070302665.USD","IE0002141913.USD","IE00BJT1NW94.SGD","LU2112291526.USD","IE00B19Z3581.USD","BK4141","IE00BMPRXR70.SGD","BK4614","LU0965508806.USD","IE0004445239.USD","LU1303367103.USD","PYPL","LU0738911758.USD","LU0390134368.USD","LU1037948541.HKD","LU0109392836.USD","LU1852331112.SGD","IE00BQXX3F31.USD","LU0170899867.USD","SG9999001440.SGD","LU1951198990.SGD","LU2089284900.SGD","NXPI","IE00BN8TJ469.HKD","BK4599","AMDD","LU0011850046.USD","LU0198837287.USD","LU1718418525.SGD","LU1917777945.USD","BK4592","LU1988902786.USD","LU0106831901.USD","BK4534","LU2106854487.HKD","LU0081259029.USD","LU0106261372.USD","LU1066053197.SGD","LU1894683348.USD","LU0861579265.USD","LU0965509010.AUD","LU0432979614.USD","IE00BD6J9T35.USD","IE00BMPRXN33.USD","LU0823434583.USD","SG9999014575.USD","LU1064131342.USD","SG9999002232.USD","BK4106","BK4612","LU0265550359.USD","LU1983299246.USD","PEP","BK4573","IE00B3T34201.USD","LU0289739699.SGD","LU1061106388.HKD","PFE","LU2023250843.SGD","LU2247934214.USD","LU1941712264.USD","LU0225771236.USD","IE000M9KFDE8.USD","BK4604","BK4505","BK4516","LU2264538146.SGD","SG9999014567.USD","LU1242518931.SGD","SG9999003800.SGD","BK4227","LU1116320901.HKD","LU2133065610.SGD","LU0321505868.SGD","AMD","BK4561","LU0823421333.USD","BK4551","LU0056508442.USD","LU0175139822.USD","BK4550","LU0965509101.SGD","SG9999011175.SGD","LU1861219969.SGD","LU0640476718.USD","BK4532"],"gpt_icon":1},{"id":"2608687301","title":"辉瑞公布GLP-1新药数据：可实现稳定减重","url":"https://stock-news.laohu8.com/highlight/detail?id=2608687301","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608687301?lang=zh_cn&edition=full","pubTime":"2026-02-03 20:02","pubTimestamp":1770120163,"startTime":"0","endTime":"0","summary":"南方财经2月3日电，辉瑞公司2月3日公布了其超长效注射型GLP-1受体激动剂PF-08653944的最新2b期临床研究结果。数据显示，在为期28周的试验中，该药物表现出显著的减重效果，经安慰剂对照调整后的平均减重幅度达12.3%。辉瑞称，该研究达到了主要终点，且在转为每月给药一次的方案后，患者体重仍持续下降。在安全性方面，该药物表现良好，副作用主要集中在轻度至中度的胃肠道反应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3bb44f7c125c909d9d8be6d6af593a67","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033640312952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0306806265.USD","LU0321505439.SGD","IE00BLSP4452.SGD","SG9999001176.SGD","BK4599","LU0225284248.USD","BK4592","IE000M9KFDE8.USD","BK4590","SG9999001176.USD","SG9999011175.SGD","BK4007","LU0170899867.USD","LU0868494617.USD","PFE","SG9999002224.SGD","LU1057294990.SGD","LU0289739699.SGD","LU0985481810.HKD","SG9999013999.USD","LU1023059063.AUD","BK4144","BK4581","IE00BLSP4239.USD","LU0225771236.USD","SG9999003800.SGD","BK4534","BK4568","LU1066051498.USD","IE0002270589.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4585","LU0058720904.USD","IE00BBT3K403.USD","LU0456855351.SGD","BK4550","BK4533","LU0234572021.USD","SGXZ57979304.SGD","LU1894683264.USD","LU1894683348.USD","LU1883839398.USD","IE00B19Z3B42.SGD","SG9999002232.USD","BK4588","LU0306807586.USD","LU0122379950.USD","LU0321505868.SGD"],"gpt_icon":0},{"id":"1113666536","title":"辉瑞预计制造优化计划将在2026年和2027年分别额外节省7亿美元和2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113666536","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113666536?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:59","pubTimestamp":1770119954,"startTime":"0","endTime":"0","summary":"辉瑞公司宣布，其制造优化计划预计将在2026年实现额外7亿美元的节省，并在2027年进一步节省2亿美元。这一举措旨在提升运营效率并优化成本结构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU0170899867.USD","BK4533","BK4585","SG9999001176.USD","BK4534","LU0321505439.SGD","BK4007","SG9999003800.SGD","LU0306807586.USD","LU1057294990.SGD","LU1066051498.USD","LU0985481810.HKD","IE00BBT3K403.USD","BK4568","BK4550","LU1894683264.USD","SG9999002224.SGD","SG9999002232.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0868494617.USD","SG9999001176.SGD","LU0122379950.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","SGXZ57979304.SGD","BK4581","LU0321505868.SGD","LU0234572021.USD","IE000M9KFDE8.USD","LU0306806265.USD","LU0058720904.USD","BK4588","LU0225771236.USD","IE0002270589.USD","LU1066053197.SGD","LU1883839398.USD","LU1894683348.USD","SG9999013999.USD","PFE","LU0456855351.SGD","SG9999011175.SGD","BK4599","LU1023059063.AUD","BK4592"],"gpt_icon":0},{"id":"1170163241","title":"辉瑞预期制造优化计划首阶段将在2026年额外节省7亿美元、2027年再省2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170163241","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170163241?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:58","pubTimestamp":1770119883,"startTime":"0","endTime":"0","summary":"根据最新公布的规划，全球制药巨头辉瑞公司宣布，其制造优化计划的第一阶段预计将带来显著成本效益：2026年将实现额外节约7亿美元，2027年将进一步节省2亿美元。这项系统性增效举措将聚焦生产流程重构与资源配置优化，通过技术升级和运营整合提升整体效率。\n该战略部署延续了企业持续降本增效的路径，在应对行业挑战的同时强化供应链韧性。阶段性成果的披露为投资者提供了明确的财务指引，也反映出公司通过结构性改革提升长期竞争力的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","LU1883839398.USD","LU0289739699.SGD","LU1066053197.SGD","IE00B19Z3581.USD","IE000M9KFDE8.USD","SG9999003800.SGD","LU1894683264.USD","LU1066051498.USD","BK4599","LU0225284248.USD","SGXZ57979304.SGD","BK4588","LU0170899867.USD","BK4533","BK4568","LU0234572021.USD","LU0321505439.SGD","BK4007","IE00BLSP4239.USD","SG9999011175.SGD","LU0306806265.USD","IE00BBT3K403.USD","LU0321505868.SGD","LU0058720904.USD","SG9999002224.SGD","IE00B19Z3B42.SGD","BK4585","IE00BLSP4452.SGD","LU1023059063.AUD","BK4534","SG9999001176.SGD","LU0985481810.HKD","BK4550","SG9999013999.USD","LU0122379950.USD","LU1894683348.USD","SG9999001176.USD","LU0225771236.USD","SG9999002232.USD","LU0306807586.USD","PFE","BK4581","BK4592","IE0002270589.USD","LU1057294990.SGD","LU0456855351.SGD"],"gpt_icon":0},{"id":"2608587335","title":"辉瑞股价盘前下跌2.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608587335","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608587335?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:54","pubTimestamp":1770119673,"startTime":"0","endTime":"0","summary":"辉瑞股价盘前下跌2.1%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602033640308628.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"4466d9e38820302c3ea1a8f2a1598904","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033640308628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4550","LU0289739699.SGD","LU1023059063.AUD","SG9999011175.SGD","BK4599","SG9999003800.SGD","IE00B19Z3B42.SGD","BK4581","BK4592","BK4585","IE0002270589.USD","LU0225771236.USD","LU0306806265.USD","LU0122379950.USD","LU1066051498.USD","LU0321505439.SGD","SG9999002232.USD","LU0306807586.USD","LU1894683348.USD","BK4534","PFE","IE00BLSP4239.USD","IE00BBT3K403.USD","SGXZ57979304.SGD","SG9999001176.SGD","LU0058720904.USD","LU0456855351.SGD","LU0321505868.SGD","LU1066053197.SGD","BK4588","LU0225284248.USD","BK4007","SG9999002224.SGD","LU1883839398.USD","SG9999001176.USD","IE000M9KFDE8.USD","LU1057294990.SGD","BK4533","LU1894683264.USD","IE00BLSP4452.SGD","BK4568","LU0234572021.USD","LU0868494617.USD","LU0170899867.USD","LU0985481810.HKD","IE00B19Z3581.USD","SG9999013999.USD"],"gpt_icon":0},{"id":"1163164652","title":"辉瑞高管称肥胖研究数据提示更高剂量或可提升疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1163164652","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163164652?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:53","pubTimestamp":1770119608,"startTime":"0","endTime":"0","summary":"辉瑞公司高管表示，最新肥胖症研究数据显示，通过增加药物剂量有望实现更优疗效。这一发现为体重管理疗法的剂量优化提供了关键科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU0225284248.USD","BK4568","IE00BLSP4239.USD","LU0289739699.SGD","LU1883839398.USD","LU1057294990.SGD","BK4007","IE00BBT3K403.USD","BK4550","BK4599","LU1023059063.AUD","PFE","BK4533","LU1066053197.SGD","LU0306807586.USD","BK4581","LU1894683264.USD","LU0321505439.SGD","SG9999001176.USD","SG9999013999.USD","BK4588","LU0122379950.USD","SG9999011175.SGD","LU0985481810.HKD","LU0058720904.USD","LU0456855351.SGD","LU0225771236.USD","SG9999001176.SGD","LU0234572021.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","BK4534","LU0170899867.USD","SG9999003800.SGD","BK4585","SGXZ57979304.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","SG9999002224.SGD","SG9999002232.USD","LU0321505868.SGD","LU0306806265.USD","BK4592","IE00BLSP4452.SGD","LU1894683348.USD","IE0002270589.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":-0.0189},{"period":"1month","weight":0.055},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0794},{"period":"1year","weight":0.0289},{"period":"ytd","weight":0.0867}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.456522,"avgChangeRate":0.002542},{"month":2,"riseRate":0.456522,"avgChangeRate":-0.006419},{"month":3,"riseRate":0.6,"avgChangeRate":0.014714},{"month":4,"riseRate":0.586957,"avgChangeRate":0.018253},{"month":5,"riseRate":0.5,"avgChangeRate":0.007748},{"month":6,"riseRate":0.5,"avgChangeRate":0.002798},{"month":7,"riseRate":0.478261,"avgChangeRate":0.011357},{"month":8,"riseRate":0.456522,"avgChangeRate":0.0002},{"month":9,"riseRate":0.456522,"avgChangeRate":0.004432},{"month":10,"riseRate":0.630435,"avgChangeRate":0.013042},{"month":11,"riseRate":0.695652,"avgChangeRate":0.028255},{"month":12,"riseRate":0.5,"avgChangeRate":0.008452}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}